Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low

Status Completed

Clinical Trial Summary

Non-alcoholic fatty liver disease is excessive fat build-up in the liver with insulin resistance due to causes other than alcohol use.The obesity epidemic is closely associated with the rising prevalence and severity of nonalcoholic fatty liver disease.Currently, the only treatment modality for patients with fatty liver disease is weight loss and exercise which is challenging for most patients. Therefore, a huge need exists for an alternative approach to reducing alanine transaminase (ALT) & aspartate aminotransferase (AST) levels for these patients. Low level laser light therapy (LLLT) offers a simple, non-invasive, safe, effective and side-effect free alternative to achieving this goal, through LLLT's proven ability to effect weight loss, body circumference reduction and lipid profile modification

Clinical Trial Description

Non-alcoholic fatty liver disease (NAFLD) is a very common disorder and refers to a group of conditions where there is accumulation of excess fat in the liver of people who drink little or no alcohol. The most common form of NAFLD is a non serious condition called fatty liver. NAFLD is part of the metabolic syndrome characterized by diabetes, or pre-diabetes (insulin resistance), being overweight or obese, elevated blood lipids such as cholesterol and triglycerides, as well as high blood pressure. A few studies have suggested that weight loss may be associated with regression of fat within the liver. Therefore, the most important recommendations for people with fatty liver are to lose weight if they are overweight or obese, increase their physical activity, follow a balanced diet and unnecessary medications. Several studies have investigated low-level laser therapy (LLLT) or light-emitting diode (LED) therapy and have made advances in the understanding of the underlying mechanisms LLLT in biological systems. Few studies explain the effect of low level laser therapy on liver enzymes and non alcoholic fatty liver risk factors (as obesity).So, our goal was to perform a randomized controlled trial to investigate the effects of the LLLT on lipid profile, body weight and liver enzymes ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Fatty Liver, Nonalcoholic
Liver Function
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT04452409
Study type	Interventional
Source	Cairo University
Contact
Status	Completed
Phase	N/A
Start date	January 10, 2020
Completion date	September 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03319199` - The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver	N/A
Recruiting	`NCT05220956` - Impact of Time-restricted Feeding in NAFLD	N/A
Active, not recruiting	`NCT04067440` - Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool
Completed	`NCT04509245` - The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes	N/A
Completed	`NCT03656744` - A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)	Phase 2
Not yet recruiting	`NCT06117137` - The Impact Of SGLT2 -I on Metabolic Dysfunction -Associated Steatotic Liver Disease In Patients With Type 2 Diabetes Mellitus	Phase 3
Completed	`NCT02132780` - Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease	N/A
Active, not recruiting	`NCT04241575` - Identification of Fatty Liver With Advanced Fibrosis in Type 2 Diabetes Using Simple Fibrosis Scores and Electronic Reminder Messages	N/A
Completed	`NCT02290106` - Effects of Pitavastatin on Insulin Sensitivity and Liver Fat	N/A
Completed	`NCT03784716` - Ketogenic Diet in Non-alcoholic Fatty Liver Disease	N/A
Recruiting	`NCT05558592` - Evaluation of the Effects of Orange Consumption on Carbohydrate and Lipid Metabolism in Subjects With MAFLD (Metabolic Associated Fatty Liver Disease)	N/A
Recruiting	`NCT05855239` - Quantification of Hepatic Steatosis With Different Ultrasound Frequency
Recruiting	`NCT05877547` - A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)	Phase 2
Completed	`NCT04462562` - Quantitative US for Evaluation of Hepatic Steatosis in NAFLD	N/A
Completed	`NCT04054297` - Glycemic Index/Saturated Fatty Acid Diet and Hepatic Fat	N/A
Completed	`NCT03260543` - Efficacy and Safety of Fermented Ginseng Powder on Liver Function	N/A
Not yet recruiting	`NCT06215131` - Feasibility of Immersive Virtual Reality Dietician Program in Metabolic-dysfunction Associated Steatotic Liver Disease	N/A
Completed	`NCT03593343` - Hepatic Glycogen and Fat Oxidation	N/A
Recruiting	`NCT06257732` - Different Exercise Modalities in the Treatment of NAFLD and Their Impact on Myokines	N/A
Completed	`NCT02983669` - The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Enhanced Liver Function in Non-alcoholic Obese Fatty Liver Patients by Low Level Laser Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms